🇺🇸 FDA
Pipeline program

KEYTRUDA 25 mg/mL concentrate for solution for infusion, Placebo to MK-3475, CISPLATIN , GEMCITABINE

MK-3475-966

Phase 3 small_molecule active

Quick answer

KEYTRUDA 25 mg/mL concentrate for solution for infusion, Placebo to MK-3475, CISPLATIN , GEMCITABINE for Biliary Tract Carcinoma is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Biliary Tract Carcinoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials